Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus in individuals aged 12 years and older. This announcement adds to the adult marketing authorization already received in Canada1 and complements the adolescent label extension received in Europe in April 2025.
In addition to the adolescent data, Health Canada’s label extension application included IXCHIQ®’s antibody persistence data, which show that the vaccine’s immune response was sustained for 24 months by 97% of participants and was equally durable in younger and older adults.
Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva, said, “This approval marks another major milestone for our vaccine as chikungunya continues to pose a significant risk to people living in or traveling to endemic regions. Ensuring our vaccine is accessible to all age groups is especially important. We await further regulatory decisions from other countries where broader access will help to provide protection and lessen the burden of this potentially debilitating illness which continues to spread into previously unaffected areas.”
IXCHIQ® became the world’s first approved chikungunya vaccine in an endemic country earlier this year when the Brazilian Health Regulatory Agency (ANVISA) granted marketing authorization in adults.
Chikungunya is becoming an increasingly prominent public health issue, with recent outbreaks in Brazil, India, and China. Valneva’s partnership with The Coalition for Epidemic Preparedness Innovations (CEPI), supported by the European Union’s Horizon Europe programme, supports broader access to IXCHIQ® in Low- and Middle-Income Countries (LMICs).
Dr. Richard Hatchett, Chief Executive Officer of the Coalition for Epidemic Preparedness Innovations (CEPI), commented, “As outbreaks of chikungunya surge around the world, expanding access to vaccines is more important than ever. This approval could help to accelerate licensure of IXCHIQ® in this age group in other regions, including areas where the disease is endemic.” Health Canada’s label extension is based on positive six-month adolescent Phase 3 data which the Company reported in May 2024.
These data showed that a single-dose vaccination with IXCHIQ® induces a high and sustained immune response in 99.1% of adolescents, and that the vaccine was generally well tolerated. The Lancet Infectious Diseases, a world leading infectious diseases journal, published an article in January 2025 showing that the vaccine was generally safe and well tolerated in adolescents aged 12 to 17 years 28 days after a single injection, regardless of previous CHIKV infection.
Contact
Laetitia Bachelot-Fontaine
VP Global Communications & European Investor Relations
M +33 (0)6 4516 7099
laetitia.bachelot-fontaine@valneva.com
Joshua Drumm, Ph.D.
VP Global Investor Relations
M +001 917 815 4520
joshua.drumm@valneva.com